Study summary
Adding rituximab to ibrutinib helped people with CXCR4 mutations
72%4-year progression-free with rituximab in CXCR4-mutated WM, vs 43%
What was tested
Patient-level data from three prospective trials comparing ibrutinib plus rituximab with ibrutinib alone in MYD88-mutated WM.
What they found
- Overall, 4-year progression-free survival was 74% vs 61% (not significant).
- In CXCR4-mutated disease, it was 72% with rituximab vs 43% without.
What it means
Supports routine CXCR4 testing and combination trials.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.